share_log

HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $1.5

HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $1.5

HC Wainwright & Co. 保持对x4制药的买入评级,将目标价下调至1.5美元
Benzinga ·  11/15 02:09  · 评级/大行评级

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $5 to $1.5.

HC Wainwright & Co. 分析师Swayampakula Ramakanth 维持对x4制药(纳斯达克:XFOR)的买入评级,并将目标价从5美元下调至1.5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发